Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retigabine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Retigabine. Displaying page 1 of 1.
    EudraCT Number: 2010-020154-33 Sponsor Protocol Number: RTG113388 Start Date*: 2012-03-09
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures(≥12 years old) and Subjects with Lennox-Gastaut Syndrome (≥12 ...
    Medical condition: Uncontrolled partial onset seizures or Lennox Gastaut Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061334 Partial seizures PT
    14.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001132-60 Sponsor Protocol Number: RTG113284 Start Date*: 2012-03-09
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: Open-label, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years wit...
    Medical condition: Uncontrolled partial onset seizures or Lennox Gastaut Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061334 Partial seizures PT
    14.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002182-36 Sponsor Protocol Number: VRX-RET-E22-302 Start Date*: 2006-04-18
    Sponsor Name:Valeant Research & Development
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TWO DOSES OF RETIGABINE (900 MG/DAY AND 600 MG/DAY) USED AS ADJUNCT...
    Medical condition: Refractory Epilepsy Patients with Partial-Onset Seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000956-42 Sponsor Protocol Number: VRX-RET-E22-304 Start Date*: 2006-09-20
    Sponsor Name:Valeant Pharmaceuticals, North America
    Full Title: A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)
    Medical condition: Adult epilepsy patients with partial-onset seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017744-14 Sponsor Protocol Number: RGB113905 Start Date*: 2010-07-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures.
    Medical condition: Epilepsy - partial-onset seizures with or without secondary generalisation
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) DK (Completed) IT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022777-34 Sponsor Protocol Number: RTG113413 Start Date*: 2011-02-01
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905).
    Medical condition: Epilepsy - partial-onset seizures with or without secondary generalisation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) ES (Prematurely Ended) BG (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001431-20 Sponsor Protocol Number: CHDR1417 Start Date*: 2015-08-17
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor ...
    Medical condition: Amytrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003105-10 Sponsor Protocol Number: PTG116878 Start Date*: 2013-01-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Study PTG116878, a Dose-Optimization Study of ezogabine/retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures.
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002396-35 Sponsor Protocol Number: XPF-009-301 Start Date*: 2021-11-15
    Sponsor Name:Xenon Pharmaceuticals Inc.
    Full Title: A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects with KCNQ2 Developmental and Epileptic Encephalopathy
    Medical condition: KCNQ2 Developmental and Epileptic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003447-28 Sponsor Protocol Number: XPF-009-302 Start Date*: 2021-10-29
    Sponsor Name:Xenon Pharmaceuticals Inc.
    Full Title: An Open-Label Extension Study of XEN496 in Pediatric Subjects with KCNQ2 Developmental and Epileptic Encephalopathy
    Medical condition: KCNQ2 Developmental and Epileptic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:33:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA